Status:
COMPLETED
Comparative Analysis of Anti-COVID-19 (Severe Acute Respiratory Syndrome) Humoral and Memory T Cell Responses in Children With Various Degrees of Immunosuppression:
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Immune Response
Eligibility:
All Genders
1-15 years
Brief Summary
Adaptive immune responses are essential for clearing viral infections and retention of virus specific memory populations is required for long-term immunity. However, there is still uncertainty about w...
Detailed Description
Adaptive immune responses are essential for clearing viral infections and retention of virus specific memory populations is required for long-term immunity. However, there is still uncertainty about w...
Eligibility Criteria
Inclusion
- Children over 0 days and under 16 years of age seen in consultation for the follow-up of their pathology or immunosuppressive treatment (see above, Groups of patients).
- Several cases groups will be considered in this study, presented with immunocompromised state or immunosuppressive treatment (i. e. children with: HIV infection, Hematologic Malignancy treated by conventional chemotherapy, Hematologic pathology treated by allogenic stem cell transplantation, inflammatory bowel disease treated by anti-TNF, idiopathic juvenile arthritis treated by methotrexate, treated by renal transplantation; see above, paragraph groups of patients for details).
- Children over 0 days and under 16 years of age considered as control will be non-immunosuppressed children without chronic inflammation, attending consultation for preoperative assessment or congenital abnormalities of the kidney and urinary tract, for Nephropathies without renal impairment (eDFG \> 45mL/min/1.73m), for non-inflammatory intestinal (polyposis, Chronic intestinal pseudo-obstruction, short bowel syndrome) or pancreatic (hereditary pancreatitis) pathologies.For comparisons, healthy children will be age-matched with each case.
- Informed consent of the holder (s) of the exercise of parental authority
- Affiliation to a social security scheme
Exclusion
- Children who have a signs of a current infection.
- Use of immunoglobulins or blood products within 3 months prior to enrolment.
- Children who received one or more doses of SARS-Cov-2 vaccine.
Key Trial Info
Start Date :
June 7 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 7 2022
Estimated Enrollment :
205 Patients enrolled
Trial Details
Trial ID
NCT04916847
Start Date
June 7 2021
End Date
December 7 2022
Last Update
March 3 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hôpital Robert Debré
Paris, France, 75019